FindTrial
Sign In

CIK cell

BIOLOGICAL4 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Chuan An Biotechnology Co., Ltd., Beijing GoBroad Hospital

Conditions

Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaFirst-line TreatmentHepatocellular CarcinomaNon-small Cell Lung CancerRefractory Acute Lymphoid LeukemiaSquamous Cell Carcinoma

Phase 1

A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA
NCT03124498
Chuan An Biotechnology Co., Ltd.Hepatocellular Carcinoma
Start: 2017-11-30End: 2019-06-30Target: 55Updated: 2017-04-21
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
NCT03987867
Tianjin Medical University Cancer Institute and HospitalFirst-line Treatment, Non-small Cell Lung Cancer
Start: 2019-06-01End: 2021-06-01Target: 30Updated: 2020-07-07

Phase 2

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
CompletedNCT01631357
Tianjin Medical University Cancer Institute and HospitalNon-small Cell Lung Cancer, Squamous Cell Carcinoma
Start: 2014-12-31End: 2018-12-31Updated: 2019-11-05

Unknown Phase

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
RecruitingNCT06389305
Beijing GoBroad HospitalAcute Lymphoblastic Leukemia, in Relapse, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoid Leukemia
Start: 2024-05-27End: 2026-05-30Target: 213Updated: 2026-02-25

Related Papers

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
2024-04-0321 citations
Long-term outcome for patients with advanced non‒small-cell lung cancer treated by autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy: NSCLC-CCICC-002.
Journal of Clinical Oncology2023-06-011 citations
Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
Frontiers in Oncology2022-09-095 citations
A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer
Clinical Lung Cancer2022-07-2135 citations
CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer
Cell Death and Disease2022-05-0642 citations
A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)-CCICC-002.
Journal of Clinical Oncology2021-05-202 citations